Monoclonal Antibody Infliximab Biosimilar from Canada
A recombinant chimeric monoclonal antibody targeting TNF-alpha, used for treating inflammatory conditions like rheumatoid arthritis. It qualifies under HTS 3002.90.52.50 as an immunological product directly involved in immune regulation, produced via biotechnological processes. Administered intravenously for therapeutic purposes.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Provide biotech origin certificates and stability data for FDA import review
• Ensure single-use vial packaging documentation to meet sterile injectable standards
• Differentiate from research-grade antibodies to avoid Chapter 98 exclusions